People with and without AD have a different threshold for elective revascularisation

February 15, 2021

The risk of both mortality and rehospitalisation after an elective revascularisation procedure for coronary artery disease is similar for people with and without Alzheimer's disease (AD), but people with AD had worse outcomes after an emergency procedure, according to a new study from the University of Eastern Finland.

Previous studies have investigated the effectiveness of revascularisation in persons with cognitive disorders, but only in terms of short-term outcomes and in acute care settings, and they also have not accounted for electivity. Similar to previous studies, people with Alzheimer's disease were 76% less likely to undergo a revascularisation procedure and only a third of the procedures were elective, compared to 48.6% of elective procedures in the comparison group without AD.

People with Alzheimer's disease had a higher risk of mortality in the procedural unit, and a 1.42-fold mortality rate during a 3-year follow-up, compared to people without AD. However, the risks were similar for elective procedures in persons with and without AD. Sociodemographic characteristics, comorbidities, statin use, length of stay and required support at discharge were controlled for in the analyses. The results were similar for both revascularisation procedure types studied, i.e., coronary artery bypass graft surgery (CABG) and percutaneous coronary interventions (PCI).

These observations on a lower rate for elective revascularisations and comparable outcomes after revascularisation procedures indicate a different threshold for elective procedures compared to emergency ones, and a very different selection for people with major cognitive disorders.

The study was conducted as part of the Medication Use and Alzheimer's Disease Study (MEDALZ), in a cohort which includes 70,718 Finnish community dwellers with Alzheimer's disease, and a matched comparison cohort. This study was restricted to people who had no previous revascularisation.
The study was published in the Journals of Gerontology: Series A, and it was funded by the Schlumberger Foundation and the Academy of Finland.

For further information, please contact:

Professor, Academy Research Fellow Anna-Maija Tolppanen, School of Pharmacy, tel. +358 50 575 9530, anna-maija.tolppanen(at)

Mai Vu, School of Pharmacy, Ph.D. Student, School of Pharmacy,

Research article:

Coronary Revascularization and Postoperative Outcomes In People With And Without Alzheimer's Disease. Mai Vu, Marjaana Koponen, Heidi Taipale, Raimo Kettunen, Sirpa Hartikainen, Anna-Maija Tolppanen. The Journals of Gerontology: Series A, 2021 Jan 9. doi:10.1093/gerona/glab006

University of Eastern Finland

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to